SCHEMBL1691995

SCHEMBL1691995

Cc1ccc(-c2cn3ccc(C)cc3n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 1.00
TP53 P04637 2/20 1.00
NPC1 O15118 8/20 0.79
RAB9A P51151 8/20 0.79
KDM4E B2RXH2 7/20 0.79
PKM P14618 2/20 0.75
GAA P10253 3/20 0.68
KMT2A Q03164 2/20 0.68
POLB P06746 1/20 0.68
GFER P55789 1/20 0.68
MAPT P10636 2/20 0.67
ALDH1A1 P00352 5/20 0.64
MEN1 O00255 1/20 0.64
MITF O75030 1/20 0.64
KDM5A P29375 1/20 0.64
KDM5C P41229 1/20 0.64
PAX8 Q06710 1/20 0.64
HPGD P15428 3/20 0.59
LMNA P02545 1/20 0.59
HRH3 Q9Y5N1 5/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13325910 0.96 SMN1; SMN2 (0.93) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL13325899 0.89 SMN1; SMN2 (0.79) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL4727165 0.89 SMN1; SMN2 (0.79) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL10648324 0.89 SMN1; SMN2 (0.79) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL4727102 0.89 SMN1; SMN2 (0.79) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL972809 0.89 NPC1 (1.00) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL6393875 0.88 SMN1; SMN2 (0.79) SMN1; SMN2TP53NPC1RAB9AKDM4E
Bromide SCHEMBL1691396 0.87 NPC1 (0.97) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL15207138 0.87 SMN1; SMN2 (0.77) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL13325751 0.86 TP53 (0.75) SMN1; SMN2TP53NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US claimed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP claimed
CN-116970965-A Electrochemical incomplete hydrogenation method of imidazopyridine compound 上海兆维科技发展有限公司 2023-10-31 CN disclosed
CN-112538087-B Synthesis method of imidazopyridine compound 温州大学新材料与产业技术研究院 2021-10-15 CN disclosed
CN-109438444-B Imidazo [1, 2-alpha ] pyridine derivative, preparation method and application thereof in allochroic powder 上海甘田光学材料有限公司 2021-03-19 CN disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
US-9590266-B2 Electrolyte for lithium secondary battery and lithium secondary battery including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-03-07 US disclosed
US-9590266-B2 Electrolyte for lithium secondary battery and lithium secondary battery including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-03-07 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
CN-103012400-A Novel synthesis method of pyridino-imidazole compound UNIV SOOCHOW 2013-04-03 CN disclosed
US-20130078533-A1 ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2013-03-28 US disclosed
US-20130078533-A1 ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2013-03-28 US disclosed
EP-2573853-A1 Electrolyte for lithium secondary battery and lithium secondary battery including the same Samsung Electronics Co., Ltd. (KR) 2013-03-27 EP disclosed
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP disclosed
US-20120010188-A1 Imidazopyridine Compounds PROMIMAGEN LTD. (GB) 2012-01-12 US disclosed
EP-2376490-A1 IMIDAZOPYRIDINE COMPOUNDS Proximagen Limited (GB) 2011-10-19 EP disclosed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010188-A1 Imidazopyridine Compounds SSB, MIF, IDO1 SMN1; SMN2 1109/4885TP53 2306/4885NPC1 1153/4885
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A SMN1; SMN2 1685/4885TP53 1427/4885NPC1 4209/4885
US-20140206662-A1 Imidazopyridine Compounds SSB, NFKBIA, TPMT SMN1; SMN2 887/4885TP53 1815/4885NPC1 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.